Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Should hemoglobin be normalized in uremic patients?

R N Foley1

  • 1Department of Nephrology, Salford Royal Hospitals NHS Trust, UK. robert.foley@srht.nhs.uk

Clinical Nephrology
|September 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Consequences of Diabetes After Kidney Donation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Associations of baseline characteristics with evolution of eGFR in a referred chronic kidney disease cohort.

QJM : monthly journal of the Association of Physicians·2013
Same author

Cardiovascular disease and survival in ESRD.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·2008
Same author

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants.

Kidney international·2007
Same author

Introduction: improving outcomes in chronic kidney disease.

Kidney international. Supplement·2006
Same author

Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us?

Kidney international. Supplement·2006

Cardiovascular disease is common in chronic kidney disease (CKD) patients, with anemia being a key risk factor. Managing hemoglobin levels may improve quality of life and reduce cardiac issues in CKD.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Cardiovascular disease (CVD) is prevalent in chronic kidney disease (CKD), leading to significantly higher mortality rates.
  • Patients on dialysis face 10-20 times higher cardiovascular death rates than the general population.
  • Cardiac failure is the most common reason for hospitalization in dialysis patients within 5 years of starting therapy.

Purpose of the Study:

  • To explore the link between anemia and cardiovascular complications in CKD.
  • To investigate the role of hemoglobin management in improving outcomes for CKD patients.

Main Methods:

  • Review of experimental and clinical studies on cardiovascular system in uremia.
  • Analysis of prospective observational studies on anemia as a risk factor in CKD progression.

Related Experiment Videos

  • Examination of intervention trials on anemia management and cardiovascular outcomes.

    • Main Results:

    • Anemia is an independent risk factor for cardiovascular overload, left ventricular enlargement, failure, and death in CKD.
    • Observational studies support normalizing hemoglobin for improved left ventricular size, quality of life, and survival.
    • Intervention trials suggest benefits in quality of life and reduced cardiac remodeling with physiological anemia management.

    Conclusions:

    • The cardiovascular system in uremia exhibits premature senescence, poorly tolerating hemodynamic stress.
    • Anemia and hypertension are key modifiable factors contributing to cardiovascular complications in CKD.
    • While benefits in quality of life and cardiac remodeling are suggested, definitive evidence on reducing cardiac failure and death from anemia management in CKD is still pending.